On May 20, 2025, Petros Pharmaceuticals, Inc. was notified by the Nasdaq Hearings Panel that it would be delisted due to failing to meet minimum stockholders' equity and bid price requirements; trading will be suspended on May 22, 2025, with plans to appeal the decision.